Travere Therapeutics

TVTX · NASDAQ

$52.30+$1.81 (+3.58%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $50.49

Latest news

NewsOct 13, 11:03 AM ETErica Kollmann
FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades
Press releaseOct 12, 5:00 PM ETBusiness Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseOct 2, 10:00 AM ETBusiness Wire
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Press releaseSep 30, 9:58 AM ETPRNewswire
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Press releaseSep 23, 7:00 AM ETBusiness Wire
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Press releaseSep 21, 4:05 PM ETBusiness Wire
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Press releaseSep 17, 4:30 PM ETBusiness Wire
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
Press releaseSep 11, 5:00 PM ETBusiness Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseAug 12, 5:00 PM ETBusiness Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseAug 5, 4:30 PM ETBusiness Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
NewsAug 5, 10:01 AM ETAvi Kapoor
Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday
NewsAug 5, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsAug 5, 3:16 AM ETMohd Haider
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On
NewsAug 4, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseAug 4, 4:01 PM ETBusiness Wire
Travere Therapeutics Reports Second Quarter 2026 Financial Results
Press releaseJul 28, 4:30 PM ETBusiness Wire
Travere Therapeutics to Report Second Quarter 2026 Financial Results
Press releaseJul 27, 8:50 AM ETPRNewswire
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
Press releaseJul 10, 5:00 PM ETBusiness Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 16, 4:30 PM ETBusiness Wire
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
Press releaseJun 11, 5:00 PM ETBusiness Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 4, 10:09 AM ETBusiness Wire
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Press releaseJun 2, 7:01 AM ETBusiness Wire
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Press releaseMay 27, 4:05 PM ETBusiness Wire
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
Press releaseMay 12, 5:00 PM ETBusiness Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 7, 4:30 PM ETBusiness Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
Press releaseMay 6, 10:28 PM ETBusiness Wire
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Press releaseMay 5, 4:01 PM ETBusiness Wire
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
NewsMay 5, 2:41 PM ETAvi Kapoor
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings
NewsMay 4, 4:02 PM ET
Travere Therapeutics Q1 Adj. EPS $0.05 Beats $(0.26) Estimate, Sales $127.199M Miss $136.822M Estimate.
Press releaseMay 4, 4:01 PM ETBusiness Wire
Travere Therapeutics Reports First Quarter 2026 Financial Results
NewsMay 4, 7:11 AM ET
Earnings Scheduled For May 4, 2026
Press releaseApr 27, 4:30 PM ETBusiness Wire
Travere Therapeutics to Report First Quarter 2026 Financial Results
Press releaseApr 14, 5:00 PM ETBusiness Wire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsApr 14, 12:30 PM ETAvi Kapoor
Crude Oil Falls Sharply; Wells Fargo Earnings Miss Views
Press releaseApr 14, 7:00 AM ETGlobe Newswire
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
NewsFeb 19, 4:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsFeb 19, 4:04 PM ET
Travere Therapeutics Q4 Earnings Report: What Investors Need to Know
NewsDec 24, 11:06 AM ETAvi Kapoor
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Participate at Upcoming Investor Conferences

Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

12 Health Care Stocks Moving In Tuesday's After-Market Session

Travere Therapeutics Reports Second Quarter 2026 Financial Results

Travere Therapeutics to Report Second Quarter 2026 Financial Results

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics Q1 Adj. EPS $0.05 Beats $(0.26) Estimate, Sales $127.199M Miss $136.822M Estimate.

Travere Therapeutics Reports First Quarter 2026 Financial Results

Earnings Scheduled For May 4, 2026

Travere Therapeutics to Report First Quarter 2026 Financial Results

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crude Oil Falls Sharply; Wells Fargo Earnings Miss Views

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

12 Health Care Stocks Moving In Thursday's After-Market Session

Travere Therapeutics Q4 Earnings Report: What Investors Need to Know

Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday